A pilot study of essential tremor: cerebellar GABA+/Glx ratio is correlated with tremor severity

Sofie Tapper1,2†, Nathanael Göransson3†, Peter Lundberg1,2, Anders Tisell1,2* and Peter Zsigmond4

Abstract

Objective: Essential tremor is a common movement disorder with an unclear origin. Emerging evidence suggests the role of the cerebellum and the thalamus in tremor pathophysiology. We examined the two main neurotransmitters acting inhibitory (GABA+) and excitatory (Glx) respectively, in the thalamus and cerebellum, in patients diagnosed with severe essential tremor. Furthermore, we also investigated the relationship between determined neurotransmitter concentrations and tremor severity in the essential tremor patients.

Methods: Ten essential tremor patients (prior to deep brain stimulation surgery) and six healthy controls, were scanned using a 3 T MR system. GABA+ and Glx concentrations were measured using magnetic resonance spectroscopy (MRS) performed using single voxel MEGA-PRESS. For the purpose of assessing the tremor severity, the essential tremor rating scale (ETRS) was used in accordance with Fahn, Tolosa, and Marin.

Results: We demonstrated that the cerebellar GABA+/Glx ratio was positively correlated to the ETRS (r = 0.70, p = 0.03) in essential tremor. Cerebellar and thalamic GABA+ and Glx concentrations did not show any significant difference when comparing essential tremor patients with healthy controls, at the group level.

Conclusion: We demonstrated a positive correlation between increasing tremor disability and the ratio of GABA+/Glx in the cerebellum of essential tremor patients. This highlights the impact of an altered balance of the excitatory and inhibitory neurotransmitters in tremor severity. Rather than a change in GABA+, which was constant, we attribute this finding to an overall decrease of Glx.

Keywords: Essential tremor, GABA, Glutamate, Magnetic resonance spectroscopy, MEGA-PRESS

Introduction

Essential tremor (ET) is one of the most common movement disorders with a prevalence of 4.6% in patients over 65 years old [1]. The diagnosis of ET is generally based on a thorough analysis of clinical history, including a neurological examination by a movement disorder specialist. The upper limbs are affected in 95% of patients, that result in shaking of the hands and forearms during simple voluntary movements [2, 3]. In addition, a wide range of other symptoms can appear (cognitive, psychiatric and other motor symptoms); the clinical diversity makes ET a very heterogenic disease [3, 4]. Not surprisingly, the pathophysiology of ET is therefore still not completely understood [5].

Recent advances in neuroimaging and spectroscopy opens up for the study of a novel range of structural, functional and metabolic changes in these patients [5]. Resting state functional MRI (fMRI) studies have shown...
decreased functional connectivity of the cerebellar network in ET [6]. Also significant alterations have been observed in the cerebello-thalamo-cortical network in patients with ET, which correlated with the overall tremor severity [7]. In addition, this network is the most common target for deep brain stimulation (DBS) surgery in ET. Several imaging studies support a cerebellar involvement in ET, where for example alterations in the grey matter volume of several brain regions including the cerebellum in ET has been observed [8]. An fMRI study showed an association between tremor and ipsilateral cerebellar activity [9], and a ‘positron emission tomography’ (PET) study showed an increased cerebellar blood flow in ET [10]. These and other studies suggests that both the cerebellum and the thalamus play a central role in the pathophysiology of ET [11–13].

Postmortem studies have shown structural changes in the cerebellum of patients with ET [14–16], including a reduced number of ‘Purkinje cells’ (PCs), dendritic swelling and increased Purkinje cell torpedoes in the cerebellum [14] (i.e., neurodegeneration). PCs propagate an input to the deep cerebellar nuclei, dentate nucleus, through gamma-aminobutyric acid (GABA) which is an inhibitory neurotransmitter. A postmortem study showed a decreased number of GABA receptors in the dentate nucleus, GABA_A (35% reduction) and GABA_B (ca. 25% reduction) [17]. Moreover, PET studies using Flumazenil, which specifically binds to the GABA_A receptor have shown an increased binding in the cerebellum, but also in the thalamus and the premotor cortex [18]. Moreover, the severity of tremor has been correlated to abnormalities found in the GABA receptor binding [19], and several GABA-ergic drugs have been shown to relieve ET [20].

Climbing fibers (CF) of the cerebellum use the excitatory neurotransmitter glutamate (Glu) (see Fig. 4), and anomalies of CF-PC synaptic connections with decreased climbing fiber synaptic density in the cerebellar cortex have also been observed [15]. An altered distribution of climbing fibers and synapses extending into the outer 20% of the molecular layer, ‘Parallel fiber’ (PF) territory, has been reported [15, 16], and it has been shown that tremor severity correlates inversely with synapse CF-PC abnormalities in the PF area [21].

Proton magnetic resonance spectroscopy’ (^1H-MRS) is a tool for non-invasive metabolite quantification, including N-acetyl-L-aspartate (NAA), total choline (tChol), and total creatine (tCr). It is therefore a powerful tool to quantitatively investigate the biochemistry and metabolism in the human brain in relation to both pathologies and healthy conditions. Greater magnetic field strength (such as 3 T instead of 1.5 T) allows for an increased signal-to-noise-ratio, better temporal resolution, and also provides a larger spectral dispersion which significantly improves quantification [22]. The latter allows for the detection of metabolites of lower concentrations than otherwise.

Louis et al. investigated the GABA concentrations in large voxels including the dentate nucleus by the use of MRS. Interestingly they found that the right dentate nucleus GABA concentration was significantly higher than the GABA concentration obtained from the left side, only observed for the ET patients [23].

There seems to be a consensus about the involvement of the cerebellum and thalamus in ET, although the potential neurochemical abnormalities causing ET remain to be further elucidated. Our aim in this study was therefore to evaluate the relationship between glutamate (Glu, determined as Glx) and GABA (determined as GABA+) concentrations in the cerebellum and thalamus, in patients diagnosed with severe ET immediately prior to DBS intervention, and to compare the concentrations of these with those obtained by examining a healthy control group. Furthermore, we aimed to investigate the correlation between neurotransmitter concentrations in the ET group and the tremor severity as determined using an ET rating scale (ETRS) [24], in order to facilitate further conclusions with respect to the underlying pathology, relationship to debilitating tremor severity and metabolic alterations.

Materials and methods

This study was approved by the local ethics committee at the University Hospital in Linköping (Ref. No. 2013/403–31, P. Zsigmond), and informed written consent was received from the patients.

Subject description

Ten right-handed Caucasian ET patients (60.2 ± 9.7 years, seven males, Table 1), and six right-handed Caucasian healthy controls (HCs) (62.2 ± 11.4 years, five males) were included in this study. The patients were referred to the neurosurgical department in Linköping after being assessed and diagnosed by a movement disorder specialist. All anti tremor medication was withdrawn one week prior to MR-examination.

To assess the tremor severity in the patients and controls, the ‘essential tremor rating scale’ (ETRS) was used in accordance with Fahn, Tolosa, and Marin [24]. Only the dominant extremity was evaluated since this is the clinical routine in the department. Thus, the right upper extremity was evaluated with part A item 5 and part B items 10–14. The ETRS score was defined as the total sum score of these evaluated items, and the maximal score was 32 points (Supplementary Table 1).
Magnetic resonance measurements

The ET patients and HCs were scanned using a 3 T Philips Ingenia MR system (Philips Healthcare, Best, Netherlands), equipped with a 12-channel phased array head coil. To assure correct voxel placements in the MRS measurements, T2-weighted turbo spin echo images were acquired in coronal (Res = 0.5*0.5*4 mm³, FOV = 230*230*96), sagittal (Res = 0.5*0.5*4 mm³, FOV = 242*242*96 mm³), and axial (Res: 0.5*0.5*2 mm³ FOV = 250*250*140 mm³) orientations. Furthermore, the MRS measurements were carried out using a single voxel MEGA-PRESS pulse sequence [25–27] optimized for GABA quantification (TR/TE = 2000/68 ms, editing pulse ON at 1.90 ppm, editing pulse OFF at 7.46 ppm, water suppression MOIST, eight phase cycle steps, 20 OFF and 20 ON dynamics, total acquisition time of 10 min and 40 s). A total of four MEGA-PRESS measurements were performed, two with the voxel (30 x 30 x 30 mm³, Fig. 1a) placed bilaterally in the thalamic region, and two with the voxel (35 x 25 x 25 mm³, Fig. 1d).

Table 1 Description of the ET patients. Each patient’s age and sex, history of ET, if treated with medication, if a current smoker, and the weekly ethanol intake are summarized. The ETRS score, thus the sum of the evaluated items, is also shown for each patient.

| Patient | Age | Sex | History of ET | Medication | Smoker | Ethanol | ETRS score |
|---------|-----|-----|---------------|------------|--------|---------|------------|
| 1       | 51  | M   | > 20 years    | 0          | No     | < 1 drink/week | 21        |
| 2       | 76  | M   | > 10 years    | 0          | No     | < 1 drink/week | 14        |
| 3       | 67  | M   | > 10 years    | 0          | No     | < 1 drink/week | 23        |
| 4       | 67  | M   | > 10 years    | 0          | No     | < 1 drink/week | 16        |
| 5       | 41  | M   | 10 years      | 0          | No     | < 1 drink/week | 15        |
| 6       | 59  | F   | 8 years       | 0          | Yes    | 1 drink/day    | 21        |
| 7       | 69  | F   | 4 years       | 0          | No     | < 1 drink/week | 17        |
| 8       | 60  | M   | > 15 years    | 0          | No     | < 1 drink/week | 17        |
| 9       | 63  | F   | > 20 years    | 0          | No     | < 1 drink/week | 15        |
| 10      | 53  | M   | > 20 years    | 0          | No     | < 1 drink/week | 17        |

Fig. 1 Representative voxel placements. Representative voxel placements (a and d) and corresponding thalamic (b-c) and cerebellar (e-f) spectra. Assignments: 1, Creatine (−CH2); 2, Glx (−CH+); 3, Choline (−N(CH3)_2); 4, Creatine (−N(CH3)); 5, GABA+ (−4CH2); 6, tNA (−3CH2); 7, Glx (−3CH2); 8, tNA (−2CH3); 9–11, Macromolecules and lipids, −CH2−. Abbreviations: Glx, glutamate+glutamine; GABA+, γ-Aminobutyric acid (+macromolecule signal); tNA, total N-acetylaspartate (NAA + NAAG).
placed bilaterally in the cerebellar region. The placement of the voxel in the anatomy was performed by two trained neurosurgeons ensuring a comparable placement among the ET cases and healthy controls. The reproducibility of the MEGA-PRESS measurements in cerebellar region was investigated and reported elsewhere [28]. After each MEGA-PRESS measurement, a shorter identical measurement but with unsuppressed water, was acquired to obtain a reference of water within the tissue in the voxel. This measurement was used for phase correction and water scaling of the resulting concentrations. Finally, since no macromolecular suppression was performed when acquiring the data in this study, the term GABA+ (GABA plus co-edited macromolecular signals) formed when acquiring the data in this study, the term GABA+ (GABA plus co-edited macromolecular signals) will be used throughout this report.

The MRS datasets were phase-corrected according to Klose [29] and frequency-aligned prior to averaging. For the purpose of GABA+ quantification, a resulting difference spectrum was computed by subtracting the averaged OFF spectrum from the averaged ON spectrum. Furthermore, due to the difficulty in separating glutamate from glutamine in the spectra, these concentrations are often reported as a combined measurement termed ‘Glx’. Only OFF data, which were unaffected by the GABA-editing pulses were used in the Glx quantification. After post-processing of the data, the difference spectra and averaged OFF spectra were quantified using LCModel (Version 6.3-1 L) [30], using simulated basis sets obtained from the Dydak Lab (December 14th 2018) [31, 32]. Figure 1 shows representative thalamic (B-C) and cerebellar (E-F) spectra fitted by LCModel. Finally, as a quality assurance, all spectra were visually inspected after LCModel fitting.

Statistical analyses
Since the investigated subjects were not considered to be normally distributed, a non-parametric approach was used in the statistical analyses. As previously described, the main focus of this report was on the cerebellar and thalamic GABA+ and Glx concentrations acquired from the left and right hemispheres. However, to increase the power of the measurements, a bilateral measurement, thus, an average of the left and right computed concentrations was also computed and investigated. Furthermore, the GABA+/Glx ratio was also investigated to exclude any potential issues that might result from the water scaling.

First, the unpaired non-parametric Mann-Whitney test was used to compare the computed concentrations and ratios obtained from the ET patient group to the resulting concentrations obtained from the healthy controls. Second, due to a previous reported cerebellar GABA+ asymmetry [23], the Mann-Whitney test was also used to investigate a potential thalamic or cerebellar asymmetry of GABA+ in the ET patient group. Third, correlation analyses were performed, correlating the GABA+ and Glx concentrations, and the GABA+/Glx ratio to the computed ETRS score defined previously. These correlation analyses were only performed for the ET patient group, and the Spearman correlation coefficients and corresponding p-values were computed to show significance. Finally, a significance level of p = 0.05 was chosen for all analyses. No correction for multiple comparisons was applied.

Results
The ET patients and HCs were similar in demographic factors and in clinical variables such as ethanol intake and handedness. Table 1 shows the ETRS score for each patient, and Supplementary Table 1 summarizes the score from each ETRS item for each patient, evaluated for the patients’ right upper extremity. The mean computed ETRS score over the ET patient group was 17.6 ± 2.9, which indicates a high overall tremor severity of this patient population. Meanwhile, all subjects in the healthy control group had an ETRS score of 0.

GABA+ and Glx concentrations
One of the patient’s Glx-measurements (from the right thalamic voxel) was discarded after quality inspection of the fitted spectra. Therefore, the corresponding bilateral measurement was computed using only the left thalamic Glx concentration. All other spectra passed this visual inspection, and corresponding computed concentration were used in further analyses.

Figure 2 illustrates the average computed GABA+ and Glx concentrations, and also the GABA+/Glx ratios for the cerebellar (A) and thalamic (B) measurements. No significant differences between the ET and HC groups were observed in the bilateral, left and right GABA+ and Glx concentrations or in the corresponding GABA+/Glx ratios. Furthermore, a non-significant higher mean Glx concentration was observed in both the cerebellar and thalamic voxel placements for the HC group compared to the ET patients.

Potential GABA+ asymmetry
We did not observe any significant differences between GABA+ concentrations in the left and right hemispheres (either for the thalamic (p = 0.85) or the cerebellar (p = 0.35) voxels, Supplementary Figure 1). However, generally a higher right cerebellar GABA+ concentration was observed, which agrees with previously reported results [23]. We did not observe any lateral differences of thalamic GABA+ concentrations.
Bilateral MRS concentrations correlated to ETRS score
Bilateral cerebellar or thalamic GABA+ and Glx concentrations did not show any significant correlation to ETRS (Fig. 3, A-B and D-E). However, the cerebellar GABA+/Glx ratio was positively correlated to the ETRS ($r = 0.70, p = 0.03$, Fig. 3c). This positive correlation was due to the reduction in cerebellar Glx and a small increase in cerebellar GABA+ with a higher tremor severity. No significant correlation was observed between thalamic GABA+/Glx ratios and tremor severity (Fig. 3f).

Cerebellar GABA+/Glx correlated to ETRS score
Since the bilateral GABA+/Glx ratio was positively correlated to the ETRS, the left and right sides are reported separately in Supplementary Figure 2. The right cerebellar GABA+/Glx ratio was significantly correlated to ETRS ($r = 0.73, p = 0.02$), whereas only a positive trend ($r = 0.51, p = 0.14$) was observed for the left side.

Discussion
In the present study we have demonstrated the presence of neurometabolic changes in the cerebellum of patients with ET, which were correlated to ETRS. To our knowledge this is the first study to show a positive correlation between the ratio of GABA+ and Glx in the cerebellum of ET patients, and increasing tremor disability suggesting a pathological correlation. Our interpretation is that this can be attributed to an overall decrease of Glu, rather than an increase in GABA+, which was constant. This suggests that an increasing ETRS score is partly due to a disturbance in cerebellar Glu-concentration, and that there is a greater impact of low Glx concentration on tremor severity than a change of GABA+.
concentration. Moreover, a greater ratio between the two main neurotransmitters acting in an inhibitory manner (GABA+) and an excitatory manner (Glx) on the synaptic level respectively, seems to correlate with a more severe tremor. This highlights the importance of the balance between the two excitatory and inhibitory neurotransmitters for proper motor control.

**Spatial origin of disease**
Recent mechanistic research on ET has focused on anomalies localized in the cerebellum, in particular Purkinje cells and the dentate nucleus [33]; these sites are schematically labeled (1) and (2) in Fig. 4. Treatment of therapy resistant ET can include ‘Deep Brain Stimulation’ (DBS) of the ventral intermediate nucleus of the thalamus or the dentatorubrothalamic tract, and therefore both the cerebellum and thalamus were examined in this study. Moreover, the pathology in ET is not static, and the symptoms often progress and spread to other cerebellar areas [3]. In addition, previous reports have shown a correlation to increasing tremor severity with abnormalities; the latter included decreased cerebellar cortical NAA/tCr [34], CF-PC synaptic pathology [21], both suggesting cerebellar neurodegeneration. Also, increased thalamic Glx concentration and Glx/Cr ratio values [35] have both been shown to correlate to tremor severity. Our findings suggest an additional, previously unreported, perspective on the pathological process in the cerebellum.

We did not find a significant difference in GABA concentration (see Fig. 2), which is in accordance with previous studies, in which a reduction of the number of GABA receptors was observed, but not a reduction in the cerebellar GABA concentration [17]. MEGA-PRESS MRS at 3 T in our application did not allow us to spatially separate signals from the dentate nucleus and cortical Purkinje cells, which is illustrated schematically by the red dotted square in Fig. 4. Thus, we have to interpret the results as a combination of the outcome of cellular events within all of these tissues (see Fig. 1).

**Aspects of tissue structure**
Tremor is the most prevalent movement disorder, but it represents a wide range of etiologies and it may represent a number of progressive diseases [36]. Moreover, clinical-, pathological and pharmacological heterogeneity may explain why evidence regarding etiology is difficult to conclude. A number of morphological aberrations have been identified in ET, mainly affecting Purkinje cells. In contrast, no pathological morphological changes have been found for other regions involved in the motor network (including the thalamus).

Previous observations include a reduced number of Purkinje cells (PCs), dendritic swelling and increased
Purkinje cell torpedoes in the cerebellum [14], and an increased number of heterotopic Purkinje cells, localized in the molecular layer of the cerebellar cortex [37]. In contrast, a number of other studies have failed to show evidence of Purkinje cell loss [38, 39]. A difference in response to pharmacological substances further elucidates the heterogeneity of the disease.

**Is the disease symmetric, or not?**

Similar to our observations, Louis and co-workers [23] did not find a reduction in GABA+ concentration in the dentate nucleus of ET using MEGA-PRESS, compared to the control subjects. Asymmetries of metabolic changes in ET have previously been reported, and Louis and co-workers did find an asymmetry, as the concentration of GABA in the right dentate nucleus was c. 15% larger than the concentration on the left dentate nucleus. This also agrees with our observations as we did not detect a GABA reduction, but an asymmetric distribution of GABA in the cerebellar region of interest. The latter was, in the patient cohort described here, limited to a trend (representing c. +10% concentration difference of GABA+, R vs. L), and therefore was not a significant effect.

In the context of symmetry, it is important to consider aspects such as objective asymmetry in clinical expression, asymmetry in perceived disability (cf. dominant hand), as well as tissue asymmetry in terms of tissue structure and biochemical parameters. Contralateral low thalamic NAA/Cr ratio was found in ET patients with predominantly tremor of the right arm [40], and clinical asymmetry of tremor was correlated to a significant degree with cerebellar pathology [41]. All of our patients perceived more symptomatic tremor on the right side, thus displaying an asymmetry from a clinical perspective. This may explain why significant correlation of GABA+/Glx versus ETRS was only detected on the ipsilateral cerebellar side (see Supplementary Figure 2), although one potential limitation of this observation of the side-to-side difference may be the limited sample size.

**Inhibitory input**

The Purkinje cells convey their input to the deep cerebellar nuclei through GABA, the main inhibitory neurotransmitter, which binds to synaptic GABA receptors. Flumazenil, which specifically binds to the GABA_A receptor, has been shown in PET studies to map the binding in the cerebellum (dentate nucleus), but also in the thalamus and the premotor cortex [18]. Other PET studies have also shown that the severity of tremor was correlated to abnormal GABA receptor binding [19]. In addition, a previous study showed a reduction of GABA...
receptors but not in GABA concentration in the cerebel-
um [17]. Available medication is very non-specific, but
certain vectors that increase GABAergic transmission
can be effective in treating ET, although with very vari-
able outcomes [42].

Purkinje cells receive two direct excitatory inputs
(Glu), from climbing fibers and from parallel fibers
[43]. (See also Fig. 4) Notably, the synaptic distribu-
tions of the climbing fibers appear to be important to
to control Purkinje cell physiology and therefore normal
cerebellar function. A particularly interesting finding,
which affects the climbing fiber to Purkinje cell syn-
aptic connections, was the observation that synaptic
density in the molecular layer of the cerebellar cortex
was associated with tremor severity [15]. A lower syn-
aptic climbing fiber-Purkinje cell density would subse-
quently result in a lower degree of inhibition of the
dentate nucleus. Furthermore, it has been shown that
the excitatory amino acid transporter 2 (EAAT2) is
reduced in the cerebellar cortex and increased in the
dentate nucleus in patients with ET, indicating that
the glutamatergic synaptic transmission is altered
[44]. The combined post-mortem observations of
these studies showed that the excitatory input (i.e.,
Glu-input) was disturbed both in the Purkinje cells
and at the dentate nucleus in ET patients. Our inter-
pretation is that the observed lower glutamate con-
centrations (expressed in terms of reduced Glx
concentrations) further advocate the role of altered
 glutaminergic transmission in ET.

What about the thalamus?
Neurogenic excitatory output from the cerebellum is
propagated to the thalamus, which is suggested to
have a role in the pathogenesis of ET. Interestingly,
the effects of a focal stroke can ameliorate the symp-
toms, as has been reported by Duncan [45]. Metabolic
abnormalities with low NAA/Cr ratio of the contralat-
eral thalamus in ET patients with predominantly
tremor of the right arm have been reported [40]. In a
recent study, the Glu-concentration was increased in
the thalamus of ET patients and correlated to tremor
severity, suggesting that thalamic glutamatergic trans-
mision is involved in the pathophysiology [35]. No
significant differences in thalamic GABA+, Glx or
GABA+/Glx between the ET and HC groups were
observed in our study. Furthermore no correlation
with GABA+/Glx and tremor severity was seen in the
thalamus. The voxel placed in our series is larger and
extends beyond the thalamic anatomical borders, thus
involving the brain areas in the vicinity of the thal-
amus (see Fig. 2). Our thalamic results are therefore
not easily comparable with previous reports and this
may be the reason why our results differ.

Limitations
Certain experimental aspects of this work were restricted
by safety, hardware, partial volume and/or techniques.
The patient cohort examined here were all diagnosed by
a movement disorder specialist, and then referred to the
neurosurgical department, thus they constituted a lim-
ited, but very narrow and well-defined group (bilateral,
but right-handed tremor). Most of them had severely de-
bilitating hand tremor and they were therefore all se-
lected as being eligible for surgery. Due to the severely
disabling disease, surgery was performed immediately
after these measurements, with an excellent therapeutic
outcome; all patients were also significantly better after
surgery (data not shown), indicating the uniquely well-
defined cohort.

Unfortunately, the measurements could not be re-
peated after the surgery, both for ethical and for safety
reasons, as the acceptable exposure to electromagnetic
fields of the DBS-implants was not compatible with the
pre-surgical examination conditions (i.e., 3 T and the
SAR level required), and this was a limitation of the
present work. At a later time (likely within a few years?)
when a sufficiently acceptable set of MR safety condi-
tions have been developed, this may nevertheless be pos-
sible to perform.

When performing GABA detection, there are several
technical aspects to be considered, one being the com-
plex nature of the spectral scalar coupling pattern of the
GABA resonances, and also due to the low signal inten-
sity compared to the other metabolite signals in the
spectra. Additionally, another major issue is spectral
overlapping by the more intense creatine signal at 3.00
ppm, which obscures the GABA signal at 3.01 ppm se-
verely. In addition, spectral editing is needed to reveal
the GABA+ signal, and single voxel MEGA-editing is
currently the standard technique. Moreover, as we are
quantifying difference spectra (using water scaling in
LCModel), a high signal-to-noise ratio (SNR) is neces-
sary; thus, we need a sufficiently large number of signal
averages and also a large spectral voxel to achieve a high
enough SNR for reliable concentration quantification of
the resulting spectra. In comparison with conventional
MRS, MEGA-PRESS requires a substantially larger voxel
volume, which results in tissue heterogeneity between
Purkinje cells and the dentate nucleus etc.

Compared to Louis et al. [23] we used a larger voxel in
our cerebellar measurements (35 × 25 × 25 mm³, which
is equivalent to 21.9 mL compared to 25 × 25 × 25 mm³,
15.6 mL). Thus, in our measurements of cerebellar tissue
we analyzed part of the cerebellar cortex, in combination
with the deep cerebellar nuclei and white matter tracts
in the cerebellum. Furthermore, to compensate for the
large SNR reduction when using a smaller voxel size,
Louis et al. collected more signal averages (196 ON/OFF
the signal typically represents Glu [48]. The largest Glu composite but of Glu and Gln, although a majority of GABA+ mainly reflect changes in GABA. Glx is also a fraction (about 40% carnosine, which is often considered to be a constant proportion of macromolecules, and probably also homo-

carried laboratories.

Since we base our argument on the ratio between GABA+ and Glx, it is of interest to consider what we have measured. The GABA+ measurements include a proportion of macromolecules, and probably also homocarnosine, which is often considered to be a constant fraction (about 40–50%); thus, any short-term changes in GABA+ mainly reflect changes in GABA. Glx is also a composite but of Glu and Gln, although a majority of the signal typically represents Glu [48]. The largest Glu to Gln ratios at the cellular level have been observed in excitatory terminals of parallel fibers in the molecular layer, and also in mossy and climbing fibers, corresponding to a concentration ratio of about 80% Glu (of Glx); and the lowest ratios have been observed in glial cells [49]. Another parameter to consider is that most Gln in the brain is less metabolically active than Glu. Please also note that MRS is typically acquired at a much lower spatial resolution, and the partial volume effects of a wide range of different cell populations then make it harder to predict a neurotransmitter ratio accurately based on cellular concentrations. However, our interpretation is that the majority of the Glx-resonances in the cerebellum are indeed Glu, and this agrees with a report by Goryawala which determined a concentration ratio of between 2 and 4 in gray matter, corresponding to c. 70% Glu (of Glx) in the cerebellum and close 80% in the brain [50].

Determination of absolute concentrations is typically recommended as this will facilitate comparison between different tissues and subjects [22]. Usually, this is achieved by the use of LCModel analysis in combination with water scaling, which is much preferred to creatine-ratios. In the cerebellum, in consideration of the relative tissue heterogeneity, water scaling appears to be less effective due to the spatial (including intra vs. extra-cellular) tissue variation of water content. This is the likely cause of the relatively large variation of the GABA+ and Glx concentrations in Fig. 3a and b. Instead, the uniquely functionally coupled ratio between the related neurotransmitters GABA and Glu will remove the effects of such spatial variation (see Fig. 3c). It is also worth noting that another difference between our study and some others, was the limited number of included ET patients and healthy control subjects (here 10 ET patients and six HCs). However, our patients belonged to a highly selective cohort of ET patients intended for DBS therapy, which may show stronger disease-related parameters.

Conclusions

This is to our knowledge the first study to show a correlation between the GABA+/Glx ratio in the cerebellum and increasing tremor disability. A change of balance between excitatory and inhibitory neurotransmitters related to a tremor rating scale (ETRS) could explain part of the pathophysiology of ET. This is rather attributed to a decrease in tissue Glu-concentration, than an altered GABA+ concentration, suggesting that an increasing ETRS score is partly due to a disturbance in cerebellar Glu concentration. Importantly, we interpret this as being a consequence of an overall decreased stimulatory effect on the inhibitory Purkinje cells, subsequently leading to decreased influence on nucleus dentatus driving the tremor. This finding may open up a range of entirely new therapeutic alternatives, which so far have been largely unexplored. The exact neurochemical abnormalities underlying ET remain to be elucidated in a larger study.
Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s40673-020-00116-y.

Additional file 1.
Additional file 2.
Additional file 3.

Acknowledgements

Richard Edden is gratefully acknowledged for very generously providing the MEGA-PRESS pulse sequence and other tools that were developed under NIH GRANTS P41 015909 and R01 016089.

Authors’ contributions

PZ, PL, AT, NG and ST contributed to the conception and design of the study. PZ, NG and AT were responsible for recruiting the patients and healthy controls and for the clinical interviews. PZ, AT, NG and ST were responsible for data acquisition and statistical analysis. All authors were responsible for preparing the manuscript and all authors approved the final version of the article.

Funding

The research was funded by the County of Östergötland. The research did not receive grant from the commercial sector. Open access funding provided by Linköping University.

Availability of data and materials

The MRI and clinical data that support the findings in this study are available publicly available due to regulations of the County of Östergötland. The MRI and clinical data that support the findings in this study are available on reasonable request from ST, AT and the last author PZ. Raw data are not provided by Linköping University.

Ethics approval and consent to participate

The study was approved by the by the ethics committee at the University Hospital in Linköping (Ref. No. 2013/403–31, P. Zsigmond), and informed written consent was received from the patients and healthy controls.

Competing interests

The authors of this article declare no competing interests.

Author details

1 Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden. 2 Department of Medical Radiation Physics and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. 3 Department of Biomedical Engineering, Linköping University, Linköping, Sweden. 4 Department of Neurosurgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Received: 3 April 2020 Accepted: 29 May 2020
Published online: 26 June 2020

References

1. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord. 2010;25(5):534–41.
2. Klaming R, Annese J. Functional anatomy of essential tremor: lessons from neuroimaging. AJNR Am J Neuroradiol. 2014;35(8):1450–7.
3. Rajput A, Robinson CA, Rajput AH. Essential tremor course and disability: a clinicopathologic study of 23 cases. Neurology. 2000;6(2):932–4.
4. Louis ED. Essential tremors: a family of neurodegenerative disorders? Arch Neurol. 2000;56(10):1202–8.
5. Shariff S, et al. Neurouromaging essentials in essential tremor: a systematic review. NeuroImage Clin. 2014;5:217–31.
6. Benito-León J, Louis ED, Romeo JP, et al. Altered functional connectivity in essential tremor: a resting-state fMRI study. Medicine (Baltimore). 2015;94(49):e1936.
7. Lenka A, et al. Role of altered cerebellum-thalamo-cortical network in the neurobiology of essential tremor. Neuroradiology. 2017;59(2):157–68.
8. Cao H, et al. A voxel-based magnetic resonance imaging morphometric study of cerebral and cerebellar gray matter in patients under 65 years with essential tremor. Med Sci Monit. 2018;24:3127–35.
9. Contarino MF, et al. Is there a role for combined EMG-MRI in exploring the pathophysiology of essential tremor and improving functional neurosurgery? PLoS One. 2012;7(10):e46234.
10. Jenkins IH, et al. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol. 1993;34(1):82–90.
11. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. Mov Disord. 1994;9(2):193–6.
12. Deuschl G, Wennerburger R, Raethjen J. Tremor. Curr Opin Neurol. 2000;13(4):437–43.
13. Critchley E. Clinical manifestations of essential tremor. J Neurol Neurosurg Psychiatry. 1972;35(3):365–72.
14. Louis ED, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. Brain. 2007;130(12):3297–307.
15. Lin CY, et al. Abnormal climbing fibre-Purkinje cell synaptic connections in the essential tremor cerebellum. Brain. 2014;137(Pt 12):3149–59.
16. Lee D, et al. Climbing fiber-Purkinje cell synaptic pathways across essential tremor subtypes. Parkinsonism Relat Disord. 2018;51:24–9.
17. Paris-Robidas S, et al. Defective dentate nucleus GABA receptors in essential tremor. Brain. 2012;135(Pt 1):105–16.
18. Boecker H, et al. GABAergic dysfunction in essential tremor. an 11C-flumazenil PET study. J Nucl Med. 2010;51(17):1030–5.
19. Gronell A, et al. GABA and serotonin molecular neuroimaging in essential tremor: a clinical correlation study. Parkinsonism Relat Disord. 2012;18(7):676–80.
20. Marin-Lahoz J, Gronell A. Linking essential tremor to the cerebellum: neurochemical evidence. Cerebellum. 2016;15(3):324–52.
21. Louis RJ, et al. Climbing fiber synaptic changes correlate with clinical features in essential tremor. Neurology. 2015;84(22):2284–6.
22. Tissel A, et al. Procedure for quantitative (1)H magnetic resonance spectroscopy and tissue characterization of human brain tissue based on the use of quantitative magnetic resonance imaging. Magn Reson Med. 2013;70(4):905–15.
23. Louis ED, et al. In vivo dentate nucleus gamma-aminobutyric acid concentration in essential tremor vs. Controls. Cerebellum. 2018;17(2):165–72.
24. Fahn S, TE, Marin C. Clinical rating scale for tremor. Munich: Urban and Schwarzenberg; 1993.
25. Mullins PG, et al. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage. 2014;86:43–52.
26. Mescher M, et al. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11(6):266–72.
27. Mescher M, et al. Solvent suppression using selective Echo Dephasing. J Magn Reson Ser A. 1996;123(2):226–9.
28. Tapper S, Tissel A, Lundberg P. How does motion affect GABA-measurements? Order statistic filtering compared to conventional analysis of MEGA-PRESS MRS. PLoS One. 2017;12(5):e0177795.
29. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med. 1994;30:26–30.
30. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–9.
31. Dydak U, et al. In vivo measurement of brain GABA concentrations by magnetic resonance spectroscopy in smelthers occupationally exposed to manganese. Environ Health Perspect. 2011;119(2):219–24.
32. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000;13(3):129–53.
33. Pasamonti L, Ceppa A, Quattrone A. Neuroimaging of Essential Tremor: What is the Evidence for Cerebellar Involvement? NY: Tremor Other Hyperkinet Mov; 2012. p. 2.
34. Louis ED, et al. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neuroisci Lett. 2002;333(1):17–20.
35. Barbagallo G, et al. Increased glutamate + glutamine levels in the thalamus of patients with essential tremor: a preliminary proton MR spectroscopic study. Parkinsonism Relat Disord. 2018;47:57–63.
36. Louis ED. Understanding essential tremor: progress on the biological front. Curr Neurol Neurosci Rep. 2014;14(6):450.
37. Kuo SH, et al. Increased number of heterotopic Purkinje cells in essential tremor. J Neurol Neurosurg Psychiatry. 2011;82(9):1038–40.
38. Rajput AH, Rajput A. Significance of cerebellar Purkinje cell loss to pathogenesis of essential tremor. Parkinsonism Relat Disord. 2011;17(6):410–2.
39. Symanski C, et al. Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord. 2014;29(4):496–500.
40. Kendi AT, et al. Magnetic resonance spectroscopy of the thalamus in essential tremor patients. J Neuroimaging. 2005;15(4):362–6.
41. Louis ED, et al. Matching asymmetry of tremor with asymmetry of postmortem cerebellar hemispheric changes in essential tremor. Cerebellum. 2014;13(4):462–70.
42. Bruno E, et al. Pregabalin for essential tremor. Cochrane Database Syst Rev. 2016;10:Cd009682.
43. Hitano T. Purkinje neurons: development, morphology, and function. Cerebellum. 2018;17(6):699–700.
44. Wang J, et al. Excitatory amino acid transporter expression in the essential tremor dentate nucleus and cerebellar cortex: a postmortem study. Parkinsonism Relat Disord. 2016;32:87–93.
45. Duncan R, Bone I, Melville ID. Essential tremor cured by infarction adjacent to the thalamus. J Neurol Neurosurg Psychiatry. 1988;51(4):591–2.
46. Bogner W, et al. 3D GABA imaging with real-time motion correction, shim update and reacquisition of adiabatic spiral MRSI. Neuroimage. 2014;103:290–302.
47. Bagga P, et al. In vivo GluCEST MRI: reproducibility, background contribution and source of glutamate changes in the MPTP model of Parkinson’s disease. Sci Rep. 2018;8(1):2883.
48. Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39(1):1–36.
49. Ottersen OP, Zhang N, Walberg F. Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience. 1992;46(3):519–34.
50. Goryawala MZ, Sheriff S, Maudsley AA. Regional distributions of brain glutamate and glutamine in normal subjects. NMR Biomed. 2016;29(8):1108–16.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.